Stockscreener 앱 받기
159.08
0.25%
0.39
시장 영업 전:
157.98
-1.10
-0.69%
전일 마감가:
$158.69
열려 있는:
$156.05
하루 거래량:
4.93M
Relative Volume:
0.77
시가총액:
$197.25B
수익:
$29.79B
순이익/손실:
$9.22B
주가수익비율:
21.65
EPS:
7.3494
순현금흐름:
$10.23B
1주 성능:
+3.59%
1개월 성능:
+4.51%
6개월 성능:
+23.07%
1년 성능:
+34.95%
1일 변동 폭
$0.00
$0.00
1주일 범위
$153.00
$159.69
52주 변동 폭
$114.02
$160.51
길리어드 사이언스 Stock (GILD) Company Profile
명칭
Gilead Sciences Inc
전화
(650) 574-3000
주소
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
159.08 | 197.25B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,281.91 | 1.14T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
268.73 | 646.92B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
286.39 | 506.08B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
141.82 | 349.89B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
156.86 | 298.15B | 54.66B | 13.58B | 16.05B | 7.0171 |
길리어드 사이언스 Stock (GILD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-07-21 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2026-07-06 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2026-05-20 | 업그레이드 | Maxim Group | Hold → Buy |
| 2026-03-10 | 개시 | Jefferies | Buy |
| 2026-02-20 | 개시 | Barclays | Equal Weight |
| 2026-02-11 | 재확인 | Needham | Buy |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-08-19 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | 업그레이드 | Truist | Hold → Buy |
| 2025-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 재확인 | Oppenheimer | Outperform |
| 2025-02-18 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-13 | 업그레이드 | DZ Bank | Hold → Buy |
| 2025-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 재확인 | Maxim Group | Buy |
| 2024-04-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-02-22 | 다운그레이드 | Truist | Buy → Hold |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-09-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Reduce |
| 2023-07-24 | 재확인 | Barclays | Equal Weight |
| 2023-05-16 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 재개 | Piper Sandler | Overweight |
| 2023-01-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 재개 | BofA Securities | Neutral |
| 2022-12-09 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2022-10-31 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 재확인 | BMO Capital Markets | Market Perform |
| 2022-10-28 | 재확인 | Cowen | Outperform |
| 2022-10-28 | 재확인 | JP Morgan | Overweight |
| 2022-10-28 | 재확인 | Jefferies | Buy |
| 2022-10-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-10-28 | 업그레이드 | Truist | Hold → Buy |
| 2022-10-28 | 재확인 | Wells Fargo | Equal Weight |
| 2022-10-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-28 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-02 | 재확인 | BofA Securities | Neutral |
| 2022-02-02 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-02-02 | 재확인 | Truist | Hold |
| 2022-02-02 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Argus | Hold → Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 재개 | Piper Sandler | Neutral |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-07-30 | 재확인 | BMO Capital Markets | Market Perform |
| 2021-07-30 | 재확인 | RBC Capital Mkts | Outperform |
| 2021-04-01 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-09-30 | 재개 | Jefferies | Buy |
| 2020-09-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-31 | 재확인 | Credit Suisse | Neutral |
| 2020-07-31 | 재확인 | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 재확인 | Piper Sandler | Overweight |
| 2020-07-31 | 재확인 | RBC Capital Mkts | Outperform |
| 2020-07-31 | 재확인 | SunTrust | Hold |
| 2020-07-31 | 재확인 | Wells Fargo | Equal Weight |
| 2020-07-20 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | 업그레이드 | SunTrust | Sell → Hold |
| 2020-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-05-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | 다운그레이드 | SunTrust | Hold → Sell |
| 2020-04-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 다운그레이드 | CFRA | Hold → Sell |
모두보기
길리어드 사이언스 주식(GILD)의 최신 뉴스
Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026? - The Motley Fool
Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE? - The Motley Fool
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards? - Zacks Investment Research
What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings? - Zacks Investment Research
Gilead Sciences, Inc. (GIS.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is Gilead Stock Increasing Your Market Risk? - Trefis
What Would A Biktarvy Slowdown Do To Gilead Stock? - Trefis
Gilead Sciences Q3 2026 Earnings Preview — October 29, Street Expects $2.21 EPS - AlphaStreet
BHC Q3 Earnings Preview: Here's What You Should Know - Zacks Investment Research
Gilead Sciences Q3 2026 Earnings Preview — October 29, Street Expects $2.21 EPS - AlphaStreet
Gilead's Latest Deal Shows Big Pharma's Appetite for Oral Peptides. Which Stocks Are Worth Watching? - Benzinga
Invesco’s RSPH or iShares’ IBB: Which Healthcare ETF Is the Better Long-Term Buy? - The Motley Fool
TG Therapeutics (TGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Zacks Investment Research
Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics - Yahoo Finance
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises - Zacks Investment Research
Gilead Sciences, Inc. $GILD Stock: Citizens Financial Group Inc. RI Increases Stake - MarketBeat
VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth? - The Motley Fool
Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy? - Yahoo Finance
Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy? - The Motley Fool
Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy? - The Motley Fool
Gilead expands in I&I with $1.28B Pepstar deal for oral IL-23Ri - BioWorld News
Roundup: Gilead Acquires Oral IL-23R Inhibitor From PepStar for $1.275 Billion, Zymeworks Licenses DLL3-Targeting T Cell Engager to Roche - Pharmaceutical Executive
Gilead shops in IL-23, inking $1.3B upfront I&I deal with China’s PepStar - BioSpace
Gilead Sciences, Inc. (GISD.XC) stock price, news, quote and history - Yahoo Finance Australia
Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy? - The Motley Fool
Gilead to pay $45 million to settle kickback charges filed by Texas attorney general - STAT
Gilead to buy PepStar's inflammation drug program in $1.28 billion deal - Reuters
Gilead Agrees to $45 Million Settlement with Texas to Resolve Medicaid Claims - Texas Border Business
Gilead Sciences (GILD) vs. AMGN and VRTX: Can Oncology Growth and HIV Strength Drive a New Growth Era Beyond Acquisitions? - Yahoo Finance
Gilead to buy PepStar's inflammation drug program in $1.28 billion deal - Yahoo Finance
Gilead Sciences, Inc. (GILD) options chain - Yahoo Finance Australia
Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD - Yahoo Finance
Gilead Sciences stock may move 4.6% on Oct. 29 earnings release - Investing.com
Gilead to Present New Data on Treatment Response and Long-Term Ma - The National Law Review
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Zacks Investment Research
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance
Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026 - Business Wire
BioNTech, Gilead to test drug combination in advanced breast cancer trial - Reuters
Gilead Sciences, Inc. (GILD) stock price, news, quote and historyYahoo Finance - Yahoo Finance Singapore
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? - The Motley Fool
Gilead Sciences, Inc. $GILD Stock Sold by Crossmark Global Holdings Inc. - MarketBeat
Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note - Zacks Investment Research
Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight - GlobeNewswire Inc.
Gilead Sciences, Inc. (GILD) Options Chain - Yahoo! Finance Canada
Gilead Sciences, Inc. (GILD) Options Chain - Yahoo! Finance Canada
GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth - Zacks Investment Research
Gilead’s ‘highly competitive’ mid-stage ulcerative colitis data ‘validate’ I&I push - BioSpace
길리어드 사이언스 (GILD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
길리어드 사이언스 주식 (GILD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Comm & Corp Aff Officer |
Oct 15 '26 |
Sale |
156.22 |
3,000 |
468,660 |
113,684 |
| JOHANNA MERCIER | Officer |
Oct 15 '26 |
Proposed Sale |
156.22 |
3,000 |
468,660 |
0 |
| ANDREW DICKINSON | Officer |
Oct 15 '26 |
Proposed Sale |
156.22 |
3,000 |
468,660 |
0 |
| O'Day Daniel Patrick | Chairman & CEO |
Oct 01 '26 |
Sale |
147.90 |
15,000 |
2,218,508 |
566,683 |
| ANDREW DICKINSON | Officer |
Sep 15 '26 |
Proposed Sale |
145.29 |
3,000 |
435,870 |
0 |
| Mercier Johanna | Chief Comm & Corp Aff Officer |
Sep 15 '26 |
Sale |
144.22 |
3,000 |
432,646 |
116,684 |
| Dickinson Andrew D | Chief Financial Officer |
Sep 15 '26 |
Sale |
145.29 |
3,000 |
435,870 |
164,096 |
| JOHANNA MERCIER | Officer |
Sep 15 '26 |
Proposed Sale |
144.22 |
3,000 |
432,646 |
0 |
| O'Day Daniel Patrick | Chairman & CEO |
Sep 01 '26 |
Sale |
148.64 |
15,000 |
2,229,592 |
577,133 |
| WELTERS ANTHONY | Director |
Aug 26 '26 |
Sale |
148.62 |
18,000 |
2,675,220 |
12,894 |
1.18%
0.03%
자본화:
|
볼륨(24시간):